Venmax Drugs & Pharmaceuticals Limited (ISIN: INE154G01022) announced a significant change in its board composition. Mrs. Dakshita Jain, serving as a Non-Executive Independent Director, has tendered her resignation from the company's board, effective November 24, 2025.

Resignation Details

The company's board of directors convened a meeting on November 24, 2025, where they accepted Mrs. Jain's resignation. The key details of the resignation are as follows:

Company's Statement

Venmax Drugs & Pharmaceuticals Limited confirmed that there were no other material reasons for Mrs. Jain's departure beyond the cited personal and professional commitments. This transparency aligns with the company's commitment to good corporate governance practices.

Impact and Next Steps

The resignation of an independent director can have implications for a company's board dynamics and corporate governance structure. While the immediate impact of Mrs. Jain's departure is yet to be seen, it is common for companies to initiate the process of identifying and appointing a suitable replacement to maintain the required board composition.

Investors and stakeholders will likely keep a close eye on any further announcements from Venmax Drugs & Pharmaceuticals Limited regarding potential new appointments to the board or any changes in the company's governance structure.

As per regulatory requirements, the company has made the necessary disclosures to the stock exchanges regarding this change in board composition. This ensures that all stakeholders are kept informed of significant corporate developments that may influence their investment decisions.

Venmax Drugs & Pharmaceuticals Limited continues to operate under the guidance of its remaining board members as it navigates this transition in its leadership structure.

Venmax Drugs & Pharmaceuticals Limited (VDPL) has reported a significant increase in revenue and a return to profitability for the quarter ended September 30, 2025. The company also made progress on its proposed amalgamation with Hatri Pharma Private Limited, a move aimed at enhancing operational efficiencies and achieving economies of scale.

Financial Performance

VDPL's financial results for Q2 FY2026 show substantial improvement compared to the same period last year:

For the half-year ended September 30, 2025, the company's revenue reached Rs 252.87 lakhs, compared to Rs 27.53 lakhs in the previous year, marking a significant year-over-year growth of 818.9%.

Amalgamation Progress

The Board of Directors approved the financial statements as of September 30, 2025, for valuation purposes related to the proposed amalgamation with Hatri Pharma Private Limited. This follows the initial approval of the amalgamation on September 2, 2025.

Key details of the amalgamation include:

1. Share Exchange Ratio: Shareholders of Hatri Pharma will receive 1 equity share of Venmax for every 1 share held in Hatri Pharma.
2. Company Profiles:
   • Hatri Pharma: Net worth of Rs 1,610 lakhs and turnover of Rs 1,846.41 lakhs
   • Venmax Drugs: Net worth of Rs 857.72 lakhs and turnover of Rs 252.87 lakhs

Rationale for Amalgamation

The amalgamation aims to achieve several strategic objectives:

1. Operational and administrative efficiencies
2. Optimal utilization of infrastructure and resources
3. Cost reduction through focused operational efforts
4. Backward integration to enhance efficiencies and achieve economies of scale
5. Streamlined legal and regulatory compliance
6. Adoption of best practices and enhanced automation

Financial Position

As of September 30, 2025, Venmax Drugs reported:

• Total Assets: Rs 1,364.68 lakhs (up from Rs 516.96 lakhs on March 31, 2025)
• Total Equity: Rs 857.72 lakhs (increased from Rs 441.19 lakhs)
• Cash and Cash Equivalents: Rs 562.26 lakhs (significant increase from Rs 248.24 lakhs)

The company's improved financial position and cash flow appear to support its growth initiatives and the proposed amalgamation.

Outlook

With the strong revenue growth and return to profitability, coupled with the strategic move towards amalgamation, Venmax Drugs & Pharmaceuticals Limited appears to be positioning itself for further growth in the pharmaceutical sector. The successful completion of the amalgamation with Hatri Pharma Private Limited could potentially strengthen the company's market position and operational capabilities in the coming years.